MGMT and neoplasm: Studies suggest that MGMT methylation status may be potentially linked to aberrant activation of the VEGF pathway in the tumor microenvironment, with methylated tumors potentially exhibiting greater dependence on angiogenesis, thereby increasing sensitivity to VEGF inhibitors like BEV (12).